Distinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA

Canakinumab is a human anti-IL-1β blocking agent that effectively neutralizes IL-1β mediated signaling for treatment of systemic juvenile idiopathic arthritis (sJIA). While many patients have dramatic clinical response to IL-1 blockade, approximately one-third fail to respond, but there currently ex...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2021-05, Vol.73 (7), p.1334-1340
Hauptverfasser:	Verweyen, Emely L, Pickering, Alex, Grom, Alexei A, Schulert, Grant S
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!